|
CASTLEFORD, England, March 2, 2010 - We are pleased to announce the launch of losartan potassium film-coated
tablets available in 25mg, 50mg and 100mg strengths, in packs of 28. Losartan
is indicated for the treatment of essential hypertension(1).
CASTLEFORD, England, January 29 - We are pleased to announce the patent expiry launch of lercanidipine
hydrochloride film-coated tablets, available in 10mg and 20mg strengths in
packs of 28. Lercanidipine hydrochloride film-coated tablets are indicated
for the treatment of mild to moderate, essential hypertension(1).
CASTLEFORD, England, January 28 - We are pleased to announce the launch of dorzolamide 2% eye drops
solution available in a 5ml bottle. Dorzolamide solution is indicated as
adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive
to beta-blockers or in whom beta-blockers are contraindicated. Dorzolamide
solution is also used in the treatment of elevated intra-ocular pressure in
ocular hypertension, open-angle glaucoma and pseudo-exfoliative glaucoma[1].
CASTLEFORD, England, January 5 - Teva UK Limited has today welcomed the Department of Health's (DH)
preferred proposal on generic substitution, which follows the announcement of
a three-month consultation.
CASTLEFORD, England, December 18 - Teva UK Limited has launched generic co-beneldopa capsules in a variety
of strengths. The company says that they are the first generic to reach the
market.
LEEDS, England, November 18 - Teva UK Limited has signalled its commitment to developing biosimilar
medicines by entering the G-CSF* therapy area. The launch of its proprietary
version of filgrastim, TevaGrastim(R), marks the Company's first biosimilar*,
and represents a major addition to Teva's Hospitals portfolio.
LEEDS, England, November 18 - In the news release, "Teva Launches TevaGrastim(R) (filgrastim)" issued on
18 Nov 2009 07:00 GMT, by Teva UK Ltd over PR Newswire, due to an omission
made by PR Newswire, we did not specify that this is a black triangle drug.
The headline should have read "Teva
Launches TevaGrastim(R) (Black Triangle Drug) (filgrastim)" rather than
"Teva Launches TevaGrastim(R) (filgrastim)" as incorrectly originally
transmitted by PR Newswire. Also, directional details to an accompanying
photo should have been included in the release. Complete, corrected release
follows:
|
|
